Home › Research › Lewy body dementia
Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy
Uchikado H, Lin WL, DeLucia MW, Dickson DW.. Journal of neuropathology and experimental neurology, 2006-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Lewy bodies (LBs) are alpha-synuclein-immunoreactive neuronal inclusions with a predilection for specific cortical and subcortical regions, including the amygdala. In this study, the presence of LBs was assessed in 347 cases of Alzheimer disease (AD). In 87 cases, LB pathology was diagnostic of brainstem (n=3), transitional (n=32), or diffuse (n=52) Lewy body disease (LBD). The remaining 260 cases of AD were screened for amygdala LBs (AD/ALB) and 62 (24%) cases were found. If AD/LBD cases are included, LBs were detected in 149 (43%) cases of AD. The presence alpha-synuclein pathology was assessed in multiple brain regions of the 62 cases of AD/ALB and 57 randomly selected cases of AD, and only sparse alpha-synuclein pathology was detected in both. The burden of alpha-synuclein pathology in brainstem nuclei, amygdala, and neocortex was significant lower in AD/ALB than in AD/LBD. In comparison to AD/LBD, AD/ALB did not differ in age at death, disease duration, male-to-female ratio, brain weight, Braak neurofibrillary tangle stage, average senile plaque density, or apolipoprotein E epsilon4 allele frequency. The results suggest that AD/ALB is pathologically different from AD/LBD, suggesting that it is a neuropathologically distinct and isolated alpha-synucleinopathy.
What this study adds
Evidence grade: Low
In 347 Alzheimer's disease brains examined after death, 149 (43%) had Lewy bodies: 87 met criteria for Lewy body disease, and 62 more had Lewy bodies in the amygdala with only sparse alpha-synuclein pathology elsewhere. The study looked only at brain tissue, not at symptoms or treatment, so it informs how Alzheimer's pathology is classified, not how the disease is diagnosed or treated in life.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Uchikado, H., Lin, W. L., DeLucia, M. W., & Dickson, D. W. (2006). Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. Journal of neuropathology and experimental neurology. https://doi.org/10.1097/01.jnen.0000225908.90052.07
Vancouver
Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. Journal of neuropathology and experimental neurology. 2006. doi:10.1097/01.jnen.0000225908.90052.07. PMID: 16825955.
BibTeX
@article{uchikado2006-16825955,
author = {Uchikado, H. and Lin, W. L. and DeLucia, M. W. and Dickson, D. W.},
title = {{Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy}},
journal = {Journal of neuropathology and experimental neurology},
year = {2006},
doi = {10.1097/01.jnen.0000225908.90052.07},
pmid = {16825955},
url = {https://doi.org/10.1097/01.jnen.0000225908.90052.07}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The burden of alpha-synuclein pathology in brainstem nuclei, amygdala, and neocortex was significant lower in AD/ALB than in AD/LBD.
- The results suggest that AD/ALB is pathologically different from AD/LBD, suggesting that it is a neuropathologically distinct and isolated alpha-synucleinopathy.
Why it matters
In 347 Alzheimer's disease brains examined after death, 149 (43%) had Lewy bodies: 87 met criteria for Lewy body disease, and 62 more had Lewy bodies in the amygdala with only sparse alpha-synuclein pathology elsewhere. Compared with the Lewy body disease cases, these amygdala cases had a significantly lower alpha-synuclein burden but did not differ in age at death, disease duration, sex ratio, tangle stage, plaque density or APOE ε4 frequency, which the authors say suggests a distinct, isolated form of alpha-synucleinopathy. The study looked only at brain tissue, not at symptoms or treatment, so it informs how Alzheimer's pathology is classified, not how the disease is diagnosed or treated in life.
Study details
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neuropathology and experimental neurology) |
| Journal's citation record | 2 / 4 | Journal of Neuropathology & Experimental Neurology: journal h-index 239 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 360 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.4 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 4 / 6 | Cited 12.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 43 other studies in this library |
| Still being cited | 3 / 4 | Cited 79 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Dennis W. Dickson: h-index 218 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16825955) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/01.jnen.0000225908.90052.07
- PubMed: 16825955
- Original source →
- Free full text: Journal of Neuropathology & Experimental Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
43 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Lewy body dementia from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.